Inify Laboratories AB: Inify Laboratories - New share capital registered

Reference is made to the stock exchange announcement made by Inify Laboratories AB (the "Company") on 12 February 2025 regarding the resolution to issue 30,202,366 new shares in a private placement (the "Private Placement Shares") and 3,464,300 new shares in a subsequent offering (the "Subsequent Offer Shares").

The share capital increase pertaining to the issuance of the Private Placement Shares and the Subsequent Offer Shares has now been registered with the Swedish Companies Registration Office. The Company's new registered share capital is SEK 5,099,261, divided on 78,903,416 shares, each with a nominal value of SEK 0.064627.

The Private Placement Shares and the Subsequent Offer Shares are, subject to timely payment, expected to be delivered on or about 17 February 2025.

Advisors

SpareBank 1 Markets AS has been appointed as financial advisor in connection with the Private Placement and the Subsequent Offering. Schjødt law firm acts as legal counsel to the Company.

For further information, please contact CEO, Fredrik Palm, fredrik.palm@inify.com, or visit https://www.inify.com

This information is subject to the disclosure requirements pursuant to section 5-12 the Norwegian Securities Trading Act.

###

The future of pathology

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI -supported workflow to optimize quality and response times, initially within prostate. The concept is scalable and can be extended to other diagnoses.

The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system.

The company, based in Sweden, became independent in 2022 through a spin-off from ContextVision (https://www.contextvision.com/), with 40 years of experience within digital imaging for medical applications. It is listed on Euronext Growth Oslo under the ticker INIFY.